menu search

PASG / Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023

Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023
PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, March 6, 2023 to report its fourth quarter and full-year 2022 financial results and discuss recent business highlights. Read More
Posted: Feb 27 2023, 07:00
Author Name: GlobeNewsWire
Views: 110113

PASG News  

Passage Bio to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

By GlobeNewsWire
April 17, 2023

Passage Bio to Present at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing tr more_horizontal

Passage Bio, Inc. (PASG) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 6, 2023

Passage Bio, Inc. (PASG) Q4 2022 Earnings Call Transcript

Passage Bio, Inc. (NASDAQ:PASG ) Q4 2022 Earnings Conference Call March 6, 2023 8:30 AM ET Company Participants Stuart Henderson - Vice President, Cor more_horizontal

Passage Bio Undervalued On Price, Long-Term Gene Therapy Prospects

By Seeking Alpha
February 28, 2023

Passage Bio Undervalued On Price, Long-Term Gene Therapy Prospects

Passage Bio's most advanced gene therapy reported good early Phase 1 data. Over $200 million in cash should provide funding until more data is availab more_horizontal

Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023

By GlobeNewsWire
February 27, 2023

Passage Bio to Report Fourth Quarter and Full-Year 2022 Financial Results on March 6, 2023

PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing tra more_horizontal

Passage Bio, Inc. (PASG) CEO Edgar Cale on Q2 2022 Results - Earnings Call Transcript

By Seeking Alpha
August 6, 2022

Passage Bio, Inc. (PASG) CEO Edgar Cale on Q2 2022 Results - Earnings Call Transcript

Passage Bio, Inc. (NASDAQ:PASG ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Stuart Henderson - VP of Corporate De more_horizontal

Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
March 3, 2022

Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q4 2021 Results - Earnings Call Transcript

Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q4 2021 Results - Earnings Call Transcript more_horizontal

Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
March 3, 2022

Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q4 2021 Results - Earnings Call Transcript

Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q4 2021 Results - Earnings Call Transcript more_horizontal

Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
March 3, 2022

Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q4 2021 Results - Earnings Call Transcript

Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q4 2021 Results - Earnings Call Transcript more_horizontal


Search within

Pages Search Results: